{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:59:16Z","timestamp":1786996756444,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.seizure.2021.06.033","type":"journal-article","created":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T20:01:46Z","timestamp":1625342506000},"page":"263-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Initial levetiracetam versus valproate monotherapy in antiseizure medicine (ASM)-na\u00efve pediatric patients with idiopathic generalized epilepsy with tonic-clonic seizures"],"prefix":"10.1016","volume":"91","author":[{"given":"Sherry Kodsy","family":"Abdelmesih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Elkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Zakaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian Y.","family":"Girgis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2021.06.033_bib0001","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1684\/epd.2015.0736","article-title":"Incidence, prevalence and aetiology of seizures and epilepsy in children","volume":"17","author":"Camfield","year":"2015","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2021.06.033_bib0002","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.06.033_bib0003","first-page":"247","article-title":"Epidemiology of epilepsy in developing countries","volume":"71","author":"Senanayake","year":"1993","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.seizure.2021.06.033_bib0004","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eplepsyres.2011.03.009","article-title":"Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: a population-based study","volume":"95","author":"Wirrell","year":"2011","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.seizure.2021.06.033_bib0005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000503831","article-title":"The Epidemiology of Epilepsy","volume":"54","author":"Beghi","year":"2020","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.seizure.2021.06.033_bib0006","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s11096-018-0641-9","article-title":"Comparative efficacy of antiepileptic drugs for patients with generalized epileptic seizures: systematic review and network meta-analyses","volume":"40","author":"Campos","year":"2018","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.seizure.2021.06.033_bib0007","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.seizure.2016.01.017","article-title":"The efficacy, tolerability and safety of levetiracetam therapy in a pediatric population","volume":"36","author":"Tekg\u00fcl","year":"2016","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2021.06.033_bib0008","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.seizure.2021.06.033_bib0009","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1528-1157.2002.24501.x","article-title":"Selective blockade of N-type calcium channels by levetiracetam","volume":"43","author":"Lukyanetz","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.06.033_bib0010","unstructured":"U.C.B. Keppra (levetiracetam 250, 500, 750 and, 1000mg tablets and 100mg\/ml for solution of infusion): summary of product characteristics. London: European Medicine Agency; 2020. SmPC Keppra\u00ae (EU). Sourced from www.ema.europa.eu [accessed 13 November 2020]."},{"key":"10.1016\/j.seizure.2021.06.033_bib0011","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/11316250-000000000-00000","article-title":"Levetiracetam in childhood epilepsy","volume":"12","author":"Verrotti","year":"2010","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.seizure.2021.06.033_bib0012","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ncl.2010.03.026","article-title":"The selection of antiepileptic drugs for the treatment of epilepsy in children and adults","volume":"28","author":"Asconap\u00e9","year":"2010","journal-title":"Neurol Clin"},{"key":"10.1016\/j.seizure.2021.06.033_bib0013","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/epi.13671","article-title":"Instruction manual for the ILAE 2017 operational classification of seizure types","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.06.033_bib0014","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40263-015-0248-9","article-title":"Levetiracetam Monotherapy in Children with Epilepsy: a Systematic Review","volume":"29","author":"Weijenberg","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2021.06.033_bib0015","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2147\/NDT.S151413","article-title":"A meta-analysis of randomized controlled trials on levetiracetam in the treatment of pediatric patients with epilepsy","volume":"14","author":"Zhang","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.seizure.2021.06.033_bib0016","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.seizure.2018.02.006","article-title":"Levetiracetam monotherapy for the treatment of infants with epilepsy","volume":"56","author":"Arican","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2021.06.033_bib0017","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00431-013-2125-1","article-title":"Initial anticonvulsant monotherapy in routine care of children and adolescents: levetiracetam fails more frequently than valproate and oxcarbazepine due to a lack of effectiveness","volume":"173","author":"Bertsche","year":"2014","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.seizure.2021.06.033_bib0018","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/0883073819846804","article-title":"Effectiveness of Levetiracetam Monotherapy in Pediatric Patients With Epilepsy","volume":"34","author":"Mazur","year":"2019","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2021.06.033_bib0019","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2021.06.033_bib0020","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000265222.24102.db","article-title":"An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy","volume":"69","author":"Striano","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2021.06.033_bib0021","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jsps.2011.06.001","article-title":"Efficacy and safety of levetiracetam in pediatric epilepsy","volume":"20","author":"Elberry","year":"2012","journal-title":"Saudi Pharmaceut J"},{"key":"10.1016\/j.seizure.2021.06.033_bib0022","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.seizure.2007.07.001","article-title":"Levetiracetam monotherapy in juvenile myoclonic epilepsy","volume":"17","author":"Sharpe","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2021.06.033_bib0023","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.seizure.2014.06.006","article-title":"Evaluation of levetiracetam and valproic acid as low-dose monotherapies for children with typical benign childhood epilepsy with centrotemporal spikes (BECTS)","volume":"23","author":"Xiao","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2021.06.033_bib0024","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.seizure.2006.12.006","article-title":"Levetiracetam monotherapy for children and adolescents with benign rolandic seizures","volume":"16","author":"Verrotti","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2021.06.033_bib0025","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","article-title":"Valproic Acid and Epilepsy: from Molecular Mechanisms to Clinical Evidences","volume":"17","author":"Romoli","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.seizure.2021.06.033_bib0026","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.seizure.2010.09.014","article-title":"A 6-month prospective study on efficacy safety and QOL profiles of extended-release formulation of valproate in patients with epilepsy","volume":"20","author":"Yu","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2021.06.033_bib0027","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.braindev.2010.03.002","article-title":"Efficacy and tolerability of levetiracetam in children with epilepsy","volume":"33","author":"Li","year":"2011","journal-title":"Brain Dev"},{"key":"10.1016\/j.seizure.2021.06.033_bib0028","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.braindev.2006.09.008","article-title":"Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial","volume":"29","author":"Coppola","year":"2007","journal-title":"Brain Dev"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121002284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121002284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T02:01:27Z","timestamp":1761012087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131121002284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":28,"alternative-id":["S1059131121002284"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2021.06.033","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initial levetiracetam versus valproate monotherapy in antiseizure medicine (ASM)-na\u00efve pediatric patients with idiopathic generalized epilepsy with tonic-clonic seizures","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2021.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}